Per Fischer, MinervaX CEO

Dan­ish biotech seek­ing niche vac­cine edge against Pfiz­er snags €72M for piv­otal study

A biotech 12 years in the mak­ing has se­cured its largest fi­nanc­ing yet, and it has am­bi­tious plans for what the chief ex­ec­u­tive called a “David vs. Go­liath” ven­ture.

Min­er­vaX, based out of Copen­hagen, put out word bright and ear­ly Thurs­day that it se­cured €72 mil­lion in new fund­ing via both eq­ui­ty fi­nanc­ing and a loan. This is the biotech’s biggest fi­nanc­ing since 2020, when Sanofi and No­vo, among oth­ers, in­vest­ed $57 mil­lion (€47.4 mil­lion at the time) in Se­ries B fund­ing. €50 mil­lion of the €72 mil­lion is com­ing through a loan from the Eu­ro­pean In­vest­ment Bank.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.